Sovateltine (also known by the research code IRL‑1620) is a synthetic peptide that acts as a selective agonist of the endothelin B (ET_B) receptor. It is under investigation as a therapeutic agent for acute ischemic stroke and other neurological conditions.
Chemical and pharmacological profile
- Class: Peptide drug, endothelin B receptor agonist.
- Mechanism of action: By selectively stimulating ET_B receptors, sovateltide promotes vasodilation, neurogenesis, and angiogenesis, and has demonstrated neuroprotective effects in pre‑clinical models of cerebral ischemia.
Development and clinical evaluation
- Origin: Developed by a pharmaceutical research organization (originally identified as IRL‑1620).
- Indications under study: Primarily acute ischemic stroke; additional exploratory studies have examined its potential in neonatal hypoxic‑ischemic encephalopathy and other cerebrovascular disorders.
- Clinical trials:
- A phase II, randomized, double‑blind, placebo‑controlled trial in India evaluated the safety and tolerability of intravenous sovateltide administered within 24 hours of stroke onset. The study reported an acceptable safety profile and suggested trends toward improved functional outcomes measured by standard stroke scales.
- Subsequent phase II/III trials have been planned or initiated to further assess efficacy, optimal dosing, and long‑term outcomes.
Regulatory status
- As of the latest publicly available information (2023), sovateltide has not received marketing authorization from major regulatory agencies (e.g., FDA, EMA, CDSCO). It remains an investigational drug pending results from later‑stage clinical trials.
Potential advantages
- Selective ET_B activation distinguishes sovateltide from non‑selective endothelin receptor modulators, potentially offering neuroprotective benefits without the vasoconstrictive effects associated with endothelin A (ET_A) receptor activation.
Limitations and ongoing research
- The clinical efficacy of sovateltide for stroke treatment has not yet been definitively established; larger, multicenter phase III studies are required.
- Long‑term safety data and comparative effectiveness versus standard reperfusion therapies (e.g., thrombolysis, mechanical thrombectomy) are still being evaluated.
References
- ClinicalTrials.gov entries for studies involving IRL‑1620 / sovateltide.
- Peer‑reviewed publications reporting pre‑clinical neuroprotective effects of ET_B receptor agonists.
Note: Information reflects the status of publicly available sources up to 2023; subsequent developments may not be captured here.
